FY26 Results Presentation

• FY26 revenue growth of 28% with Q4 at 45%
• Expansion of commercial team and US market penetration
• Launch of EVA automated programming system
• FY27 revenue guidance of $113-$122M
• Introduction of new products like the Paddle Lead

Saluda Medical, Inc. presented its FY26 results, highlighting a 28% revenue growth year-over-year, with Q4 revenue at 45%. The company expanded its commercial team significantly, increasing market share by 21%. They also expanded into new territories, with US territory coverage increasing to 62% by the end of FY26. The launch of the EVA automated programming system further reduced patient management burden and improved patient outcomes. Saluda provided FY27 revenue guidance of $113-$122M, expecting continued growth from active physicians, higher utilization, and the launch of new products like the Paddle Lead.

FY27 revenue guidance of $113-$122M, gross margin of 50%-52%, and adjusted EBITDA of ($101)-($95)M

Saluda Medical anticipates continued growth in FY27 driven by an expanded sales force, increased market penetration, and the launch of new products like the Paddle Lead. They expect to gain further market share in high-volume ambulatory surgery centers and continue expanding into new territories.